Neurodegeneration and neurogenesis in mouse models of aging and Alzheimer's disease
Year: 2003
Type: dissertation
Abstract: As the proportion of senior citizens gradually increases, the behavioral changes that occur with \nnormal aging and as a consequence of Alzheimer’s disease (AD) will afflict many of us in the \nfuture. Aging is the major risk factor for AD, and pathological changes that occur in AD are \nsuperimposed upon normal aging alterations. Thus, to understand etiologies and mechanisms of \nAD it is important to distinguish normal aging from disease processes. In search of structural \nparameters, which could correlate with the behavioral changes during normal aging and AD, the \ndiscovery of neural progenitor cells and neurogenesis in the adult mammalian brain has received \nmuch attention. Furthermore, advances in stem cell techniques have raised the possibility for \nneuronal replacement strategies in neurodegenerative diseases such as AD. With progresses in \nmouse genetics and the identification of genes linked to AD it has become possible to generate \ntransgenic mouse models that mimic key aspects of AD pathology. Studies involving such mouse \nmodels have identified beta-amyloid peptide (Aβ), the main component of amyloid plaques, as \nan important factor in the pathophysiology of AD. However, no general consensus exists about \nthe mechanism by which Aβ exerts its detrimental effects. The research described herein addresses \nkey questions regarding (i) neurogenesis and its modulation in the aging mouse brain, (ii) the \nimpact of cerebral amyloidosis on neurodegeneration and neurogenesis in a transgenic mouse \nmodel of AD, and (iii) the application of a promising anti-Aβ immunotherapy in this transgenic \nmouse model. \nIn a first study, we have examined the effect of aging on neurogenesis in the dentate gyrus of \nC57BL/6 (B6) mice. We used the B6 line because it is one of the best characterized mouse \nstrains in neuroscience, and because it was shown to be relatively resistant to age-related structural \nbrain changes. Our results revealed a striking decrease in neurogenesis due to an age-related \nreduction in neuronal proliferation. Interestingly, this decrease was observed until late adulthood \nwith no further decline with aging. Stimulated by recent findings that caloric restriction (CR) \nmight increase neurogenesis in young rodents, the potential of CR to postpone the age-related \ndecrease in neurogenesis was tested. However, results revealed no impact of CR on hippocampal \nneurogenesis. Instead, a survival-promoting effect of CR on newborn glial cells in the hilar \nregion was observed. In a second study, the impact of cerebral amyloidosis on neurodegeneration was studied using a \nrecently generated murine model of AD, the APP23 mouse. This transgenic line overexpresses a \nmutated human form of the amyloid precursor protein (APP), develops amyloid plaques, and \nshows cognitive impairments with aging. Stereological estimation revealed a modest but \nsignificant age-related neuron loss in the neocortex of APP23 mice. This observation is consistent \nwith the appearance of plaque-associated apoptotic and necrotic neurons in aged APP23 mice. \nEncouraged by recent reports that demonstrated neocortical neurogenesis after targeted apoptosis, \nwe examined neurogenesis in the neocortex of APP23 mice with a high amyloid burden. However, \nno evidence for neocortical neurogenesis, both in young and aged APP23 mice, was found. \nIn contrast, we found a fivefold increase in gliogenesis in aged transgenic mice when compared \nto littermate controls. \nDuring the last few years several therapeutic strategies have been proposed for treating AD, and \nsome of them have entered clinical trials. For example, it has been suggested that vaccination \nwith Aβ reduces cerebral amyloidosis and protects against cognitive deficits in different mouse \nmodels of AD. Thus, in a third study, we investigated the effect of passive immunization in the \nAPP23 mouse, a model that exhibits amyloid plaques as well as cerebral amyloid angiopathy \n(CAA), similar to that observed in the human AD brain. Our results showed significant clearance \nof diffuse amyloid and reductions in the levels of the highly fibrillogenic Aβ42. However, \nimmunized mice exhibited a robust increase in the frequency and severity of CAA-associated \ncerebral hemorrhages compared to non-vaccinated APP23 controls. Together with the \nneuroinflammatory side effects recently observed in human trials, our results further stress the \nneed for a better understanding of the basic mechanisms involved in antibody-mediated \nAβ clearance.
Source: edoc (University of Basel)
Author: Bondolfi, Luca E.
Language: English
Subfield: Developmental Neuroscience
Field: Neuroscience
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W1506410539
